Prenatal Screening
Prenatal genetic testing provides information about whether a fetus may have certain genetic disorders. These disorders are caused by changes in a person’s genes or chromosomes. One type of condition is called aneuploidy, in which the number of chromosomes is abnormal. For example, a trisomy occurs when there is an extra chromosome, while a monosomy occurs when a chromosome is missing.
Some genetic conditions are inherited and are caused by gene mutations passed from parents to their child. Common inherited disorders include sickle cell disease, cystic fibrosis, and Tay-Sachs disease. In many of these conditions, both parents must carry the same mutated gene for the baby to be affected.
Screening tests can help identify the risk of having a baby with specific genetic conditions. These include both carrier screening and prenatal genetic screening tests, which provide helpful information to expectant parents during pregnancy.
Prenatal Screening – A cutting-edge DELFIA® technology with its patented LifeCycle™ software for non-invasive prenatal diagnosis (NIPD), providing parents a powerful, high-resolution assessment of fetal genome integrity to proactively support healthy developmental outcomes.
Double Marker Test
Measures two key markers in the mother’s blood to screen for Down syndrome and other chromosomal conditions. Recommended during the first trimester for early risk assessment.
Triple Marker Test
Analyzes three markers to assess the risk of Down syndrome, neural tube defects, and other fetal developmental issues. Usually performed in the second trimester.
Quadruple Marker Test
Includes the three triple-marker indicators plus inhibin-A, improving accuracy in detecting chromosomal abnormalities such as Down syndrome.
Penta Marker Test
An advanced screening test that adds another biomarker to the quad panel, offering higher precision in evaluating risks of chromosomal disorders.
*These are screening tests, not diagnostic. Results indicate risk levels only. Follow your doctor’s advice for any further confirmatory tests when required!!!
Prenatal Screening by Trimester:
- 1st Trimester (Dual, Triple & Quad)
- 2nd Trimester (Double, Triple & Quad)
First Trimester Screening
| Screening Strategy | Time of Test (Weeks) | Markers Used | Detection Rate (%) |
|---|---|---|---|
| Double Marker | 9–10+6 | Maternal age + Free β-HCG + PAPP-A | 60–65% |
| Combined NT Screening | 11–13+6 | Maternal age + Free β-HCG + PAPP-A + Nuchal Translucency | 93–94% |
Second Trimester Screening
| Screening Strategy | Time of Test (Weeks) | Markers Used | Detection Rate (%) |
|---|---|---|---|
| Triple Marker | 15–21+6 | AFP + Free β-HCG + Unconjugated Estriol | 65–70% |
| Quadruple Marker | 15–21+6 | AFP + Free β-HCG + Unconjugated Estriol + Inhibin-A | 70–75% |
First & Second Trimester Screening
| Screening Strategy | Time of Test (Weeks) | Markers Used | Detection Rate (%) |
|---|---|---|---|
| Sequential Test (1st Stage) | 11–13+6 | Maternal age + Free β-HCG + PAPP-A + Nuchal Translucency | 90–94% |
| Sequential Test (2nd Stage) | 15–21+6 | Maternal age + Free β-HCG + AFP + Inhibin-A + Unconjugated Estriol | 90–94% |
PRE-ECLAMPSIA SCREENING TEST
We offer the screening only on DELFIA®, based on time-resolved fluorescence technology, a FMF approved equipment, assays and software with high performance and long-term precision which is a product of choice in 90+ countries.
To learn more about Prenatal screening , contact your healthcare provider!!!
Trusted Screening Powered by Science
Ugene Labs Pvt Ltd. is a leading provider of advanced prenatal and newborn genetic screening, committed to ensuring healthier beginnings for every child.
Copyright 2025 Ugene Labs Pvt Ltd. – All Rights Reserved. Designed & Developed By Web Digital Mantra Pvt Ltd